SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon informs about updates

12 Jan 2026 Evaluate

Biocon has informed that Biocon Pharma, a wholly owned subsidiary of the Company, has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its ANDA for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg and 5 mg strengths. Everolimus Tablets for Oral Suspension are indicated for the treatment of adult and pediatric patients aged 1 year and older with Tuberous Sclerosis Complex (TSC) who have Subependymal Giant Cell Astrocytoma (SEGA) and for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. The approval will further strengthen Biocon’s portfolio of vertically integrated drug products.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

358.20 7.65 (2.18%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×